Market Overview

Morgan Stanley Sees 2014 Guidance for Tenet Healthcare as Full of Puts and Takes

Share:
Related THC
Companies That Have The Most To Lose If Obamacare Is Repealed
Watch These 10 Huge Call Purchases In Thursday Trade
Community Healthcare rally stokes buying in related firms (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst Andrew Schenker reiterated an Equal-Weight rating on Tenet Healthcare (NYSE: THC).

In the report, Morgan Stanley noted, “THC issued FY14 Adj. EBITDA guidance of $1.8B to $1.9B including reform benefit of $50M to $100M. Guidance compares with MS est. and consensus of $1.94B and 1.96B, respectively. THC's forecast assumes pro-forma admissions growth of -2% to flat adj. admissions growth of -1% to +1% and VHS synergies of $50M-$100M. Separately, the company anticipates 1Q14 adj. EBITDA of $350M-$400M including $10M in EHR, this compares with MS and street at $434M and $447M, respectively.”

Tenet Healthcare closed on Monday at $48.33.

Latest Ratings for THC

DateFirmActionFromTo
Jan 2017PiperJaffrayInitiates Coverage OnNeutral
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for THC
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (THC)

View Comments and Join the Discussion!